| Website | fidelitybioscienc... |
| Phone | 617-231-2400 |
| Employees |
They are a division of Fidelity Investments, one of the world’s leading providers of financial services. For more than 30 years, Fidelity Investments has been a significant presence in the venture capital and private equity industry, investing the firms own capital since 1969. This provides them with the flexibility, and capabilities of traditional venture capital firms while eliminating the additional pressures of fundraising. The result is a clear focus on building long-term value for Fidelity, their management partners, and co-investors.
| Company | Date | Round | Size | Participants |
| Liazon | 4/12 | Venture Round | $18.2M | 4 |
| ViewRay | 3/12 | Series C | $45M | 5 |
| Imagen Biotech | 10/11 | Series A | $40M | 3 |
| ViewRay | 9/11 | Venture Round | $10M | 5 |
| Fluidnet | 8/11 | Series C | $25M | 5 |
| Ultragenyx Pharmaceutical | 6/11 | Series A | $45M | 4 |
| Blueprint Medicines | 4/11 | Series A | $40M | 2 |
| NextWave Pharmaceuticals | 1/11 | Series C | $45M | 7 |
| Accuri Cytometers | 10/10 | Series E | $6M | 5 |
| ViewRay | 8/10 | Series C | $20M | 5 |
| Vicept Therapeutics | 6/10 | Series A | $16M | 3 |
| Foldrx Pharmaceuticals | 6/10 | Venture Round | $29M | 7 |
| Tetraphase Pharmaceuticals | 6/10 | Series C | $45M | 6 |
| Accuri Cytometers | 8/09 | Series D | $4M | 5 |
| Proteostasis Therapeutics | 8/08 | Series A | $45M | 5 |
| Mersana Therapeutics | 11/05 | Venture Round | $21M | 7 |
